Arbutus Biopharma (ABUS) Stock Statistics & Valuation Metrics

Arbutus Biopharma has a market cap or net worth of $635.71M. The enterprise value is ―.

Arbutus Biopharma has 191,480,200 shares outstanding. The number of shares has decreased by -2.65% in one year.

Arbutus Biopharma’s return on equity (ROE) is -0.72 and return on invested capital (ROIC) is -65.47%.

The current PE Ratio of Arbutus Biopharma is -8.68. Arbutus Biopharma’s PEG ratio is -0.35.

In the last 12 months, Arbutus Biopharma had revenue of 6.17M and earned -69.92M in profits. Earnings per share was -0.38.

In the last 12 months, operating cash flow was -64.61M and capital expenditures -181.00K, giving a free cash flow of -50.53M billion.

Arbutus Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―

Arbutus Biopharma upcoming earnings date is Jul 31, 2025, TBA Not Confirmed.

Arbutus Biopharma as a current ratio of 8.15, with Debt / Equity ratio of 1.32%

In the past 12 months, Arbutus Biopharma has paid 0.00 in taxes.

Arbutus Biopharma EV to EBITDA ratio is -8.36, with an EV/FCF ratio of -8.82.

Arbutus Biopharma has $122.62M in cash and marketable securities with $1.29M in debt, giving a net cash position of -$121.33M billion.

Gross margin is 88.48%, with operating margin of -1236.74%, and net profit margin of -1133.04%.

The average price target for Arbutus Biopharma is $5.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy